Document:

EX-10.t

 Exhibit 10t 
 Confidential Treatment Requested 
 TERMINATION AGREEMENT

 This Termination Agreement (the “Agreement”), is made as of January 1, 2013, by and between,
Sanofi, a French société anonyme (“Sanofi”), and Bristol-Myers Squibb Company, a Delaware corporation (“BMS” and together with Sanofi, the “Parties” and, individually, each a
“Party”) and relates to (i) the Territory A Alliance Support Agreement (the “JVA Support Agreement”), dated as of January 1, 1997, by and between Sanofi and BMS, as amended by that certain Amendment
No. 1, dated of October 17, 2001 (“Amendment No. 1”), Amendment, dated October 2, 2007 (“Amendment No. 2”) and Amendment No. 3, dated April 10, 2012 (“Amendment
No. 3” and together with, Amendment No. 1 and Amendment No. 2, the “Amendments”), (ii) that certain General Side Letter, dated January 2, 1997, from BMS to Sanofi (“General Side
Letter”) and (iii) that certain Side Letter, dated January 2, 1997, from BMS to Sanofi regarding transfer pricing (“Side Letter” and together with the General Side Letter, the “Side Letters”). Any
capitalized terms not herein defined shall have the meaning ascribed to them in the JVA Support Agreement. 
 WHEREAS, Sanofi
and BMS have formed, through their indirect wholly-owned subsidiaries, Sanofi Pharma Bristol Myers Squibb, a société en nom colletif organized under the laws of the French Republic (“JVA”); 

WHEREAS, pursuant to a master restructuring agreement (“Master Agreement”), dated as of September 27, 2012 by and
between Sanofi and BMS, Sanofi and BMS have agreed to simplify the overall governance, operating and financial principles of their alliance with respect to (i) Irbesartan Products worldwide (other than in Japan, which is not in their alliance)
and (ii) Clopidogrel Products worldwide (other than in Japan, which is not in their alliance, and in the United States) (the “Restructuring”); 
 WHEREAS, in connection with the Restructuring of JVA, Sanofi and BMS have agreed to terminate the JVA Support Agreement and the Amendments and to terminate the Side Letters solely as they relate to
Territory A; and 
 WHEREAS, on the Termination Date, Sanofi shall assume control of the distribution and commercialization of
the Products in all of Territory A and shall be responsible for all decisions relating to distribution and commercialization and the local co-promotion and co-marketing Affiliates. 

NOW THEREFORE, the Parties, in consideration of the foregoing and other good and valuable consideration (the receipt and sufficiency of
which are hereby acknowledge by each of the Parties) hereby agree by mutual consent: 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

	 	1.	Termination and Release. The Parties hereby agree and acknowledge that the JVA Support Agreement and each of the Amendments is hereby terminated, effective
January 1, 2013 (the “Termination Date”), in all respects and such that all of the respective rights of each Party are terminated and that each Party is hereby released and discharged from all future obligations and all
liabilities under the JVA Support Agreement and each of the Amendments; provided, however, that neither Party shall be released from liability associated with its acts or omissions prior to the Termination Date; provided,
further, that the Parties hereby agree that any provisions that survive pursuant to the terms of the JVA Support Agreement and each of the Amendments shall not survive beyond the Termination Date, except that Article VI (indemnification)
shall survive to the extent provided in the Master Agreement and to the extent any provision such Article VI is incorporated by reference into an Opt-out Agreement or an Autogeneric Agreement (as such terms are defined in the Master Agreement). For
the avoidance of doubt, Sections 5.02, 5.03 and 5.06 and Article IX of the JVA Support Agreement shall not survive beyond the Termination Date and, to the extent applicable, such provisions shall be superseded by the non-competition and
confidentiality provisions in the Master Agreement. 

  

	 	2.	Partial Termination of the Side Letters. The Parties hereby agree and acknowledge that the Side Letters are hereby terminated, effective on the Termination Date,
as they relate to Territory A. In connection therewith, the Parties hereby agree that all references to “Territory A,” the “Territory A Alliance Support Agreement,” the “SNC Partnership” or otherwise relating to
Territory A shall be deleted from the Side Letters and the Side Letters shall otherwise continue in full force and effect as they relate solely to Territory B, which Territory shall be amended as of the Termination Date. 

 

	 	3.	Tax Matters. In accordance with the terms of the Master Agreement, the Parties hereby agree that the following provisions shall apply as of the Termination Date
and shall survive the termination of JVA and the transfer of the interests of any partner of JVA and shall remain in effect for the period of time necessary to resolve any and all matters regarding income taxation of JVA and items of [*] to the
extent based upon events or circumstances arising, filings made with respect to periods ending on or before, or decisions made, prior to the Termination Date: 

 

	 	a.	The Parties shall cause the [*] to promptly provide each partner of JVA with copies of notices or other materials from, and inform each partner of JVA of discussions
engaged in with, all [*], and shall provide each partner of JVA with notice of all [*] including, without limitation, meetings with [*] [*], [*] and [*], as soon as possible after receiving notice of the [*]; 

 

	 	b.	The Parties shall cause the [*] and 

  

	 	c.	The Parties hereby acknowledge that the [*] may request extensions to file any tax return or statement without the written consent of, but shall so inform, [*].

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

	 	4.	Opt-Out Agreements and Autogeneric Agreements. The Opt-out Agreements and Autogeneric Agreements (as such terms are defined in the Master Agreement) shall
continue according to their terms except as otherwise provided in the Master Agreement, and any amounts payable thereunder shall be payable under the Master Agreement instead of the JVA Support Agreement. 

 

	 	5.	Conflict. In the event of any conflict between the provisions of this Agreement and the Master Agreement, the provisions of the Master Agreement shall control.

  

	 	6.	Representations and Warranties. Each of the Parties hereto represents and warrants to each other as of the date hereof that (a) it has the requisite
authority and power to enter into this Agreement and (b) the execution and delivery of this Agreement has been duly authorized and constitutes its legal, valid and binding obligation, enforceable against it in accordance with its terms.

  

	 	7.	Counterparts. This Agreement may be executed in any number of counterparts (and by different parties hereto on different counterparts), each of which shall
constitute an original, but all of which when taken together shall constitute a single contract. 

  

	 	8.	Successors and Assigns. The terms of this Agreement and the respective rights and obligations of the Parties hereunder shall be binding upon, and inure to the
benefit of, their respective successors and assigns. 

 [Remainder of Page Intentionally Left Blank]

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 IN WITNESS WHEREOF, this Agreement has been duly executed as of the date first written
above. 
  

			
	SANOFI
		
	By:	 	/s/ T. Saugier            
		 	 Name: T. Saugier
 Title:
Authorized representative

  

			
	BRISTOL-MYERS SQUIBB COMPANY
		
	By:	 	/s/ Katherine Kelly            
		 	 Name: Katherine Kelly

Title: Assistant Secretary

 [Signature Page to JVA Alliance Support Agreement Termination Agreement] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSIONEX-10.u

 Exhibit 10u 
 *Confidential Treatment Requested 
 AMENDMENT NO. 4

 TO THE 
 TERRITORY B ALLIANCE SUPPORT AGREEMENT 
 This Amendment No. 4 (this
“Amendment No. 4”), dated as of January 1, 2013 (the “Effective Date”) to the Territory B Alliance Support Agreement (“JVB Support Agreement”), dated as of January 1, 1997, as amended
by that certain Amendment No. 1, dated October 17, 2001 (“Amendment No. 1”), that certain Amendment, dated October 2, 2007 (“Amendment No. 2”) and that certain Amendment No. 3, dated
April 10, 2012 (“Amendment No. 3”) is hereby made by and between Sanofi, a French société anonyme (“Sanofi”), and Bristol-Myers Squibb Company, a Delaware corporation
(“BMS” and together with Sanofi, the “Parties” and, individually, each a “Party”). Except as otherwise noted, any capitalized terms not herein defined shall have the meaning ascribed to them in the
JVB Support Agreement. 
 WHEREAS, pursuant to a master restructuring agreement (the “Master Agreement”), dated
as of September 27, 2012, by and between Sanofi and BMS, Sanofi and BMS have agreed to simplify the overall governance, operating and financial principles of their alliance with respect to (i) Irbesartan Products worldwide (other than in
Japan, which is not in their alliance) and (ii) Clopidogrel Products worldwide (other than in Japan, which is not in their alliance, and in the United States) (the “Restructuring”); 

WHEREAS, as part of the Restructuring, the Parties wish to amend certain provisions of the JVB Support Agreement to reflect the
acquisition by sanofi-aventis U.S. LLC of the rights and obligations of Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership (“JVB”) with respect to the distribution and commercialization of the Products in the countries
set forth on Schedule 1 attached hereto (“Territory B1”) and Sanofi shall be responsible for all decisions relating to distribution and commercialization of the Products in Territory B1 as of the Effective Date; and 

WHEREAS, the Restructuring is not intended to change the overall governance, operating, and financial principles of the alliance with
respect to Clopidogrel or Clopidogrel Products in the United States. 
 NOW THEREFORE, the Parties, in consideration of the
foregoing and other good and valuable consideration (the receipt and sufficiency of which are hereby acknowledge by each of the Parties) hereby agree by mutual consent: 
  

	 	1.	Consent to the Assignment. The Parties hereby consent to the assignment, on the Effective Date, by JVB to sanofi-aventis U.S. LLC of all of its rights and
obligations to develop, manufacture, commercialize and sell the Products in Territory B1. Commencing on the Effective Date, Sanofi shall assume control of the distribution and commercialization of the Products existing as of such date and shall be
responsible for all decisions relating to the distribution and commercialization, in each case, in Territory B1. The provisions of the JVB Support Agreement shall no longer apply to countries in Territory B1, including, without limitation, any
noncompetition restrictions. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

	 	2.	Amendments. The Parties hereby agree that the JVB Support Agreement shall be amended to provide the following: 

 

	 	a.	All countries other than the United States shall no longer be included within the definition of “Territory B” in the JVB Support Agreement and, as such,
Section 1.01 of the JVB Support Agreement shall be amended to remove Territory B1 and all references to “Territory B” throughout the JVB Support Agreement shall mean solely the United States (which, in any event, shall not include
Irbesartan in the United States). 

  

	 	b.	All references to “Irbesartan” or “Irbesartan Products” throughout the JVB Support Agreement shall be deleted and the definition of
“Products” in Section 1.01 of the JVB Support Agreement, and all references throughout the JVB Support Agreement, shall mean Clopidogrel and the Clopidogrel Products only. 

 

	 	c.	All references to “Territory A,” “Territory A Alliance Support Agreement,” the “SNC Partnership” or otherwise relating to Territory A in
the JVB Support Agreement shall be deleted in their entirety and the provisions of the JVB Support Agreement relating to the management of the alliance shall no longer apply to Territory A or Territory B1. 

 

	 	d.	Article III of the JVB Support Agreement shall be amended to exclude all references to “Territory A,” “Irbesartan” and “Irbesartan
Products” and Sections 3.04 and 3.08 shall be deleted in their entirety. 

  

	 	e.	Section 5.02 of the JVB Support Agreement shall be amended and restated in its entirety as follows: 

“Section 5.02. Non-Competition. (a) During the period from and after the date hereof until the [*] each Party shall
not, and shall cause its Affiliates not to, directly or indirectly, except through the Territory B Partnership [*]. 
 (b)
Nothing contained in this Section 5.02 shall prevent BMS or any of its Affiliates from acquiring a business or being acquired by, or acquiring or combining with a Person, in each case which, at the time of such acquisition or
combination, makes, sells, promotes or otherwise commercializes: (i) any product containing Clopidogrel as an active pharmaceutical ingredient (“API”); (ii) Clopidogrel API; or (iii) intermediates useful solely for
production of Clopidogrel API; provided, that BMS and its Affiliates (which for these purposes would include an acquiror following the closing of the relevant transaction) shall dispose of API and intermediates of the Clopidogrel Products
(other than API and intermediates purchased, used or manufactured in connection with BMS Permitted FDCs) and of the relevant portion of the business or securities of the Person which undertakes the foregoing activity within [*] after the completion
of such acquisition or combination; provided further that BMS shall notify Sanofi as promptly as practicable after any such acquisition or combination. 
 (c) Nothing contained in this Section 5.02 shall prevent Sanofi or any of its Affiliates from acquiring a business, or being acquired by, or acquiring or combining with a Person, in each case
which, at the time of such acquisition or combination, makes, sells, 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

2 

 
promotes or otherwise commercializes, in Territory B: (i) any product containing Clopidogrel as an API; (ii) Clopidogrel API; or (iii) intermediates useful solely for production of
Clopidogrel API; provided, that Sanofi and its Affiliates (which for these purposes would include an acquiror following the closing of the relevant transaction) shall dispose of API and intermediates of such products (other than API and
intermediates purchased, used or manufactured in connection with Sanofi Permitted Clopidogrel FDCs) in Territory B and the relevant portion of the business or securities of the Person which undertakes the foregoing activity in Territory B (other
than with respect to Sanofi Permitted Clopidogrel FDCs) within [*] after the completion of such acquisition or combination. 

(d) BMS and its Affiliates shall have a right to use, and to have its Permitted Sublicensees use, by cross-reference, or incorporation by
reference, or any similar right or process, regulatory filings held (and any data contained therein), generated or owned by Sanofi with respect to the Clopidogrel Products (other than Excluded FDCs) prior to January 1, 2013, to enable BMS, its
Affiliates or its Permitted Sublicensees to conduct clinical trials for, and to file and obtain registrations for and commercialize a BMS Permitted FDC, if BMS desires to develop or market a BMS Permitted FDC in the United States, and at BMS’s
cost. Upon BMS’s reasonable request, Sanofi will, at BMS’s expense, promptly confirm such rights and/or answer questions that have been reasonably requested or required by an applicable regulatory authority. 

(e) Nothing contained in this Section 5.02 (subject to Section 5.02(b)) shall prevent BMS or its Affiliates from
making, selling, promoting or otherwise commercializing, in each case either directly or through Permitted Sublicensees, a BMS Permitted FDC and none of them shall be required to pay any royalties or to obtain any consent from Sanofi for any such
activities worldwide from and after January 1, 2013. 
 (f) Nothing contained in this Section 5.02 (subject to
Section 5.02(b)) shall prevent Sanofi or its Affiliates from making, selling, promoting or otherwise commercializing, in each case either directly or through Permitted Sublicensees, a Sanofi Permitted FDC and none of them shall be
required to pay any royalties (except with respect to Identified Clopi FDCs) or to obtain any consent from BMS for any such activities worldwide from and after January 1, 2013. 

(g) Nothing in this Section 5.02 shall be deemed to create or imply a license or right to or in the other Party or its
Affiliates under any intellectual property owned or controlled by a Party or its Affiliates that covers or claims any of its proprietary compounds or molecules (except as otherwise contemplated by the Parties) with respect to Clopidogrel.

 (h) For purposes of this Section 5.02: 
 (1) “BMS Permitted FDCs” means an FDC that includes at least the following active ingredients: (a) Clopidogrel and (b) a BMS Proprietary Compound, excluding, for the period
beginning on the Effective Date and ending on December 31, 2020, FDCs containing solely Clopidogrel and acetylsalicylic acid (the “Excluded FDCs”). For the avoidance of doubt, the foregoing exclusion does not apply to any
Excluded FDC which also includes a BMS Proprietary Compound; 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

3 

 (2) “BMS Proprietary Compound” means any compound that is either owned, in
whole or in part, by BMS or its Affiliates, or is licensed exclusively or co-exclusively to or by BMS or its Affiliates, and, at the time of the initial inclusion of such compound in a combination with Clopidogrel, is covered by one or more claims
of a patent or patent application in any country; 
 (3) “FDC” or “fixed-dose combination”
means a pharmaceutical dosage form containing fixed doses of more than one active ingredient in which all active ingredients are present in a single tablet, capsule or other form and shall expressly exclude so-called “co-packaging” in
which separate drugs in separate dosage forms are sold in a single unit or bundle; 
 (4) “Permitted
Sublicensees” means entities: (a) that will be manufacturing, developing or registering Products on behalf of BMS, including pursuant to co-commercialization or co-development agreements (for the purpose of manufacturing, development
or registration); or (b) to whom BMS sublicenses a Qualified FDC (but, in the case of this clause (b), only for use with such Qualified FDC); 
 (5) “Qualified FDC” means a BMS Permitted FDC with respect to which either (a) Phase II clinical trials have been completed by BMS and/or its Affiliates or the entities defined in
clause (a) of the definition of “Permitted Sublicensees,” or (b) Phase III clinical trials have been commenced by BMS and/or its Affiliates or the entities defined in clause (a) of the definition of “Permitted
Sublicensees;” 
 (6) “Sanofi Permitted Clopidogrel FDCs” means an FDC that includes at least the
following active ingredients: (a) Clopidogrel and (b) a Sanofi Proprietary Compound; and 
 (7) “Sanofi
Proprietary Compound” means any compound that is either owned, in whole or in part, by Sanofi or its Affiliates, or is licensed exclusively or co-exclusively to or by Sanofi or its Affiliates, and, at the time of the initial inclusion of
such compound in a combination with Clopidogrel, is covered by one or more claims of a patent or patent application in any country.” 
  

	 	f.	Section 7.01(a) of the JVB Support Agreement shall be amended to provide that the term of the JVB Support Agreement (the “Term”) shall expire on
December [*], 2019 (the “Expiration Date”). Thereafter, the Term may be renewed solely with respect to Clopidogrel or Clopidogrel Products in Territory B for successive three-year terms, by mutual agreement of the Parties, no later
than 24 months prior to the expiration of the term then in effect. If not renewed prior thereto, upon the Expiration Date, the process described in Section 7.07 or Section 7.08, as applicable, of the JVB Support Agreement shall apply.

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

4 

	 	g.	A new Section 7.07(vi) shall be added to the JVB Support Agreement to provide the following: “Following the Expiration Date or such later date if the Term is
extended pursuant to the terms set forth herein, [*] shall retain the responsibilities of Tax Matters partner with respect to all tax periods ending on or prior to the date of such termination. In connection therewith, [*] shall: (i) promptly
provide [*] with copies of notices or other materials from, and inform [*] of discussions with, U.S. federal and state tax authorities; (ii) provide [*] with notice of all scheduled administrative proceedings, including, without limitation,
meetings with agents of such tax authorities, technical advice, conferences and appellate hearings, in each case promptly after receiving notice of the scheduling of such proceedings and (ii) not agree to any settlement agreement with such tax
authority with respect to JVB-related items of income, gain, loss or deduction without [*] prior written consent; provided, that [*] may request extensions to file all tax returns or statements without [*] prior written consent (and [*] shall
provide [*] with notice of any such requests).” 

  

	 	h.	Article IX of the JVB Support Agreement shall be deleted in its entirety. 

  

	 	i.	A new Article X shall be added to the JVB Support Agreement to provide the following: “If during the Term Sanofi intends to abandon any patent relating to a
Clopidogrel Product in Territory B (as such term is amended pursuant to this Amendment), Sanofi shall provide BMS forty-five (45)-days advance written notice of such intent, describing in reasonable detail the patent(s) it intends to abandon and the
target date of abandonment (“Abandonment Date”). BMS shall provide Sanofi with written notice at least fifteen (15)-days prior to the Abandonment Date of its desire to assume the title of the patent (“Patent Assumption
Notice”). If Sanofi receives BMS’s Patent Assumption Notice, Sanofi shall assign to BMS the title to such patent on or before the Abandonment Date and BMS shall cover all of the costs and expenses of such assignment. If BMS fails to
provide a Patent Assumption Notice, Sanofi shall be free to abandon such patent, in its sole and absolute discretion, on the Abandonment Date or thereafter. If Sanofi assigns to BMS the title to such patent, BMS shall pay all further costs relating
to the patent, including, but not limited to, all costs and expenses relating to prosecution costs, maintenance costs and litigation costs, and Sanofi shall be relieved of all of its rights and obligations with respect to such patent after such
date. The procedures set forth herein shall apply each time Sanofi intends to abandon a patent prior to the Expiration Date.” 

  

	 	3.	Remainder of the Agreement. Except as explicitly amended hereby, other provisions of the JVB Support Agreement (as otherwise amended, modified, supplemented or
restated prior to the Effective Date) shall remain unchanged. For the avoidance of doubt, Article VI of the JVB Alliance Support Agreement shall continue in full force and effect except as expressly modified in the Master Agreement.

  

	 	4.	Representations and Warranties. Each of the Parties hereto represents and warrants to each other as of the date hereof that (a) it has the requisite
authority and power to enter into this Amendment No. 4 and (b) the execution and delivery of this Amendment No. 4 has been duly authorized and constitutes its legal, valid and binding obligation, enforceable against it in accordance
with its terms. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

5 

	 	5.	Counterparts. This Amendment No. 4 may be executed in any number of counterparts (and by different parties hereto on different counterparts), each of which
shall constitute an original, but all of which when taken together shall constitute a single contract. 

  

	 	6.	Successors and Assigns. The terms of this Agreement No. 4 and the respective rights and obligations of the Parties hereunder shall be binding upon, and
inure to the benefit of, their respective successors and assigns. 

 [Remainder of Page Intentionally Left
Blank] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

6 

 IN WITNESS WHEREOF, this Agreement has been duly executed as of the date first written
above. 
  

			
	SANOFI
		
	By:	 	/s/ T. Saugier            
		 	 Name: T. Saugier
 Title:
Authorized representative

  

			
	BRISTOL-MYERS SQUIBB COMPANY
		
	By:	 	/s/ Katherine Kelly            
		 	 Name: Katherine Kelly

Title: Assistant Secretary

 [Signature Page to Amended Territory B Alliance Support Agreement] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 SCHEDULE 1 
 TERRITORY B1 
 With respect to Irbesartan Products and Clopidogrel
Products: 
 Argentina 
 Australia 
 Brazil 

Canada 
 Mexico

 With respect to Clopidogrel Products only: 
 Colombia 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]